Download PDF
Nuklearmedizin 2002; 41(05): 202-207
DOI: 10.1055/s-0038-1625287
Editorial
Schattauer GmbH

PET in der nuklearmedizinischen Diagnostik – Kosten/Nutzen-Aspekte[*]

Further Information

Publication History

Publication Date:
11 January 2018 (online)

    Permissions and Reprints

 

* Vortrag am 15. Juni 2002 in Würzburg anlässlich des Symposiums zum 75. Geburtstag von Prof. Dr. Wilhelm Börner


 

  • Literatur

  • 1 Coleman RE, Tesar R, Phelps M. HCFA and expanded coverage of PET. J Nucl Med 2001; 42: 11N-12N.
    Google Scholar
  • 2 Dietlein M, Weber K, Gandjour A. et al. Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany. Eur J Nucl Med 2000; 27: 1441-56.
    CrossrefGoogle Scholar
  • 3 Dietlein M, Weber K, Gandjour A. et al. Cost-effectiveness of FDG-PET for the management of the surgically treatable non-small cell lung cancer (NSCLC): Priority for a PET-based strategy after nodal negative CT results. Eur J Nucl Med 2000; 27: 1598-609.
    CrossrefGoogle Scholar
  • 4 ECRI. Positron emission tomography (PET) for the diagnosis and staging of non-small-cell lung cancer, part 1: results of ECRI’s meta-analysis. Health technology assessment information service; 1998 No. 72.
    Google Scholar
  • 5 ECRI. Positron emission tomography (PET) for the diagnosis and staging of non-small-cell lung cancer, part 2: cost-effectiveness analysis. Health technology assessment information service; 1998 No. 73.
    Google Scholar
  • 6 Gambhir SS, Hoh CK, Phelps ME. et al. Decision tree analysis for cost-effectiveness of FDGPET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996; 37: 1428-36.
    Google Scholar
  • 7 Gambhir SS, Shepherd JE, Shah BD. et al. Analytical decision model for the management of solitary pulmonary nodules. J Clin Oncol 1998; 16: 2113-25.
    CrossrefGoogle Scholar
  • 8 Goldman L, Weinstein MC, Goldman PA. et al. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991; 265: 1145-51.
    CrossrefGoogle Scholar
  • 9 Hay JW, Wittels EH, Gotto Jr AM. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am J Cardiol 1991; 67: 789-96.
    CrossrefGoogle Scholar
  • 10 Jungehülsing M, Scheidhauer K, Damm M. et al. 2(18F)-Fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg 2000; 123: 294-301.
    CrossrefGoogle Scholar
  • 11 Kosuda S, Ichihara K, Watanabe M. et al. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-Fluoro-2-D-[18F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung cancer) in Japan. Chest 2000; 117: 346-53.
    CrossrefGoogle Scholar
  • 12 Laupacis A, Feeny D, Detsky AS. et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146: 473-81.
    Google Scholar
  • 13 Littenberg B, Garber AM, Sox Jr HC. Screening for hypertension. Ann Intern Med 1990; 112: 192-202.
    CrossrefGoogle Scholar
  • 14 Park KC, Schwimmer J, Shepherd JE. et al. Decision analysis for the cost-effective management of recurrent colorectal cancer. Ann Surg 2001; 233: 310-9.
    CrossrefGoogle Scholar
  • 15 Reske SN, Kotzerke J. Results of the 3rd German Interdisciplinary Consensus Conference, »Onko-PET III«, 21 July and 19 September 2000. Eur J Nucl Med 2001; 28: 1707-23.
    CrossrefGoogle Scholar
  • 16 Scott WJ, Shepherd J, Gambhir SS. Cost-effectiveness for FDG-PET for staging non-small cell lung cancer: a decision analysis. Ann Thorac Surg 1998; 66: 1876-85.
    CrossrefGoogle Scholar
  • 17 Simoons ML, Casparie AF. Therapy and prevention of coronary heart diseases through lowering of the serum cholesterol levels; third consensus »Cholesterol«. Consensus Working Group, CBO. Ned Tijdschr Geneeskd 1998; 142: 2096-2101.
    Google Scholar
  • 18 Tengs TO, Adams ME, Pliskin JS. et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15: 369-90.
    CrossrefGoogle Scholar
  • 19 Van Tinteren H, Hoekstra OS, Smit EF. et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomized trial. Lancet 2002; 359: 1388-92.
    CrossrefGoogle Scholar
  • 20 Tosteson AN, Rosenthal DI, Melton LJ, Weinstein MC. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 1990; 113: 594-603.
    CrossrefGoogle Scholar
  • 21 Wright JC, Weinstein MC. Gains in life expectancy from medical interventions – standardizing data on outcomes. N Engl J Med 1998; 339: 380-6.
    CrossrefGoogle Scholar
  • 22 Eddy DM, Hasselblad V, McGivney W, Hendee W. The value of mammography screening in women under age 50 years. JAMA 1988; 259: 1512-9.
    CrossrefGoogle Scholar